11 – 20 of 317
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia : A review of the literature
(
- Contribution to journal › Scientific review
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in children with severe haemophilia A and B-Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts
(
- Contribution to journal › Article
-
Mark
Dilemmas on emicizumab in children with haemophilia A : A survey of strategies from PedNet centres
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
- 2022
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article